Recent findings showcasing the efficacy of the ONECUT2 inhibitor CSRM617 in suppressing tumor growth and metastasis in mouse models have positioned ONECUT2 as a potential therapeutic target [4]. Here, ONECUT2 is linked to neoplasm.